USA flag logo/image

An Official Website of the United States Government

SBIR Phase I:De novo assays for detection of the proteolytic activity in…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
99105
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
1013945
Solicitation Year:
N/A
Solicitation Topic Code:
BT5
Solicitation Number:
N/A
Small Business Information
BIOSENTINEL, LLC
510 Charmany Drive Suite 259 Madison, WI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: SBIR Phase I:De novo assays for detection of the proteolytic activity in botulinum neurotoxin-based pharmaceuticals
Agency: NSF
Contract: 1013945
Award Amount: $150,000.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I project proposes to develop a universal, in vitro assay for determining the enzymatic activity of botulinum neurotoxin (BoNT)-based pharmaceuticals. BoNTs are used in many cosmetic and pharmaceutical applications due to their long lasting effects and specificity for motor neurons. Currently, the strength and quality of BoNT-based pharmaceuticals is assessed using a mouse bioassay where BoNT is injected into mice and a unit of activity depends on the rate or proportion of deaths. Beyond animal testing concerns, the mouse bioassay's inaccuracy and the lack of standardized protocols among manufacturers put patient safety and clinical outcomes at risk. The proposed technology will reduce animal use and provide a method to uniformly assess the activity of BoNT-based pharmaceuticals regardless of manufacturer, thus increasing patient safety and the likelihood of successful treatment. The broader/commercial impacts of this research are increased patient safety, reduced animal testing, and the potential to enable point-of-use/point-of-care testing. The proposed technology could be used for decontamination testing at manufacturing sites, authenticity (against counterfeit drugs) testing at border control points, and in-office testing for high-dose procedures where toxin concentration is critical for clinical outcomes. The proposed technology would be the first of its kind on the commercial market. Other commercially available assays are not suitable for assessing BoNT-based pharmaceuticals because formulation stabilizers interfere with the assays. The proposed technology could be further adapted for testing BoNT activity in highly complex matrices extending the technology's utility into food, water, biodefense, and environmental testing.

Principal Investigator:

Ward Tucker
DPhil
6084418172
wtucker@biosentinelpharma.com

Business Contact:

Ward Tucker
DPhil
6084418172
wtucker@biosentinelpharma.com
Small Business Information at Submission:

BioSentinel
1568 Luneta Drive Del Mar, CA 92014

EIN/Tax ID: 202547375
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No